Cerus Corporation (NASDAQ: CERS) today announced financial results for the fourth quarter and year ended December 31, 2013.
“The coming year will be a pivotal one for Cerus, in which we anticipate a possible second-half approval decision for INTERCEPT plasma in the United States, and prepare for a possible INTERCEPT platelet approval decision in 2015,“ said William “Obi” Greenman, president and chief executive officer of Cerus Corporation.
Help employers find you! Check out all the jobs and post your resume.
